Abstract: A percutaneous absorption preparation for the treatment of dementia wherein the drug-containing layer contains donepezil or a pharmaceutically acceptable salt thereof as an active ingredient and a stabilizer that is either (i) a mixture of a thiocyanate salt and a compound selected from the group consisting of tea catechin, (+)-catechin, epigallocatechin gallate, ascorbic acid, and isoascorbic acid, or (ii) a mixture of monothioglycerol and a compound selected from the group consisting of tea catechin, (+)-catechin, epigallocatechin gallate, and ascorbic acid is disclosed. The percutaneous absorption preparation meets the criteria of Procedure 1 and Procedure 2 of the U.S. Pharmacopoeia in short-term stress test (70° C. 48 hours storage), long-term accelerated test 1 (40° C. relative humidity 75% 1 month storage), and long-term accelerated test 2 (40° C. relative humidity 75% 3 months storage), and exhibits improved stability for long-term preservation.

Abstract: A percutaneous absorption preparation including donepezil for the treatment of dementia is disclosed. The percutaneous absorption preparation for the treatment of dementia includes a support layer, a drug-containing layer, and a release layer, wherein the drug-containing layer contains donepezil or a pharmaceutically acceptable salt thereof as an active ingredient; monothioglycerol, thiocyanate metal salt (preferably potassium salt) or dimethylthiourea as a stabilizer; and a pressure-sensitive adhesive. Also disclosed is a percutaneous absorption preparation for the treatment of dementia with reduced the formation of donepezil impurities.

Abstract: A battery thermal treatment apparatus including, a thermal treatment part, in which a battery is transferred and thermally treated through a closed tube; and a gas handling part, which cools and performs dust collection of gas generated in the thermal treatment part, and, a method for battery thermal treatment and performing dust collection of thermal treatment gas, including, cooling and performing dust collection of gas generated during thermal treatment of a battery, which is transferred and in one direction through a closed tube, thermally treated at a temperature ranging from 400° C. to 1000° C., and discharged.

Abstract: A percutaneous absorption preparation is disclosed. The percutaneous absorption preparation contains donepezil for treatment of dementia, wherein the preparation includes: (a) donepezil or its pharmaceutically acceptable salt as active component, (b) propylene glycol monocaprylate as solubilizer, and (c) styrene-isoprene-styrene block copolymer (“SIS”) as adhesive. The percutaneous absorption preparation has low skin irritation and high skin penetration.

Abstract: The present invention relates to a pharmaceutical composition for forming a film directly on a wound to accelerate wound healing, a use for the same, a treatment method using the same, and a method for preparing the same. The film-forming composition according to the present invention forms a film directly on the wound to increase the adhesion to the wound. The formed thin hydrophilic film protects the wound surface to prevent infection of the wound surface, retains the physiologically active substance useful for wound healing on the wound surface to promote the wound healing, and allow drugs to be continuously delivered to the wound surface. Therefore, the composition according to the present invention has excellent wound healing effect and has excellent usability as it is not absorbed into clothing, bandage, etc., thus effectively replacing conventional gel or ointment formations for delivering physiologically active substances.

Abstract: A battery thermal treatment apparatus including, a thermal treatment part, in which a battery is transferred and thermally treated through a closed tube; and a gas handling part, which cools and performs dust collection of gas generated in the thermal treatment part, and, a method for battery thermal treatment and performing dust collection of thermal treatment gas, including, cooling and performing dust collection of gas generated during thermal treatment of a battery, which is transferred and in one direction through a closed tube, thermally treated at a temperature ranging from 400° to 1000°, and discharged.

Abstract: Provided is a composition of a ready-to-use injectable solution comprising pemetrexed or pharmaceutically acceptable salts thereof, containing pemetrexed; anhydrous sodium sulfite; and N-acetyl-L-cystein. With respect to use as an injectable preparation. The ready-to-use injectable solution composition is suitable for effective administration of pemetrexed since a melting process of main ingredients is not necessary before administration, and the composition can be used by being diluted immediately in a perfusate. In addition, the properties of the composition do not change even in long-term storage, and pharmaceutical stability is significantly improved by inhibiting related substances below a reference, whereby the composition can be stored in a liquid preparation state.

Abstract: The present invention relates to a novel liquid composition comprised of piroxicam or its pharmaceutically acceptable salt (a non-steroid anti-inflammatory drug) and hyaluronic acid or its pharmaceutically acceptable salt (used for treatment of degenerative arthritis). Specifically, the invention provides a highly physicochemically stable liquid injection, comprising piroxicam and hyaluronic acid as active ingredients and ?-cyclodextrin or its derivative and polyethylene glycol as additives to enhance its physicochemical stability, and the preparation method thereof.

Abstract: A pharmaceutical composition for the treatment of osteoarthritis comprising piroxicam or pharmaceutically acceptable salt thereof and hyaluronic acid or pharmaceutically acceptable salt thereof at a specific ratio is provided. The composition generates synergistic effect on both anti-inflammatory and analgesic effects simultaneously. The pharmaceutical composition contains 0.25-10.0 wt % of piroxicam or its pharmaceutically acceptable salt and 0.5-5.0 wt % of hyaluronic acid or its pharmaceutically acceptable salt, wherein the weight ratio between piroxicam or its pharmaceutically acceptable salt and hyaluronic acid or its pharmaceutically acceptable salt is between 1:1 and 1:3.

Abstract: The present invention relates to a pharmaceutical composition for forming a film directly on a wound to accelerate wound healing, a use for the same, a treatment method using the same, and a method for preparing the same. The film-forming composition according to the present invention forms a film directly on the wound to increase the adhesion to the wound. The formed thin hydrophilic film protects the wound surface to prevent infection of the wound surface, retains the physiologically active substance useful for wound healing on the wound surface to promote the wound healing, and allow drugs to be continuously delivered to the wound surface. Therefore, the composition according to the present invention has excellent wound healing effect and has excellent usability as it is not absorbed into clothing, bandage, etc., thus effectively replacing conventional gel or ointment formations for delivering physiologically active substances.

Abstract: The present invention relates to a novel liquid composition comprised of piroxicam or its pharmaceutically acceptable salt (a non-steroid anti-inflammatory drug) and hyaluronic acid or its pharmaceutically acceptable salt (used for treatment of degenerative arthritis). Specifically, the invention provides a highly physicochemically stable liquid injection, comprising piroxicam and hyaluronic acid as active ingredients and ?-cyclodextrin or its derivative and polyethylene glycol as additives to enhance its physicochemical stability, and the preparation method thereof. Therefore, the novel composition and the formulation method thereof provided by the present invention may be used to produce a liquid injection composition of piroxicam and hyaluronic acid.

Abstract: Provided is a process for preparing a solubilized and stabilized formulation of a sirolimus derivative, which comprises the steps of a dissolving a sirolimus derivative in a solvent, and bring a solution of the sirolimus derivative into contact with a water-soluble carrier to disperse the sirolimus derivative in the water-soluble carrier, and a formulation of a sirolimus derivative with improved solubility and stability as prepared by the preparation process as above.

Abstract: Disclosed is an oral bisphosphonate formulation characterized by an enhanced clinical bioavailability of bisphosphonate and by the use of phytic acid and a delayed release means for releasing bisphosphonate at a site of the lower gastrointestinal tract. Having a low phytic acid content, the oral bisphosphonate formulation guarantees high safety to the patient. Moreover, the oral formulation is designed to allow the patients to take the medicament, together with food intake, at a bioavailability as high as that of an empty stomach, thus improving the convenience of drug administration for the patient. Therefore, the oral formulation is expected to provide higher therapeutic effects for osteoporosis.

Abstract: The present invention provides a 3?,4?,5-trimethoxy flavone derivative and a pharmaceutically acceptable salt thereof, preparation thereof, and a pharmaceutical composition for the treatment and prevention of dry eye syndrome comprising the same as an active ingredient. The 3?,4?,5-trimethoxy flavone derivative and its pharmaceutically acceptable salt inhibit corneal damage through excellent stimulatory action on mucus secretion in the conjunctiva and therefore may be effective as a prophylactic or therapeutic agent for dry eye syndrome.

Abstract: This invention relates to a controlled-release composition for producing a sustained-release preparation containing udenafil, including (A) udenafil and a pharmaceutically acceptable salt, (B) a solubility modulator, (C) an adsorbent, and (D) a hydrophilic polymer. This controlled-release composition for producing a sustained-release preparation containing udenafil releases drugs constantly regardless of the pH level in the gastrointestinal tract, and thus freely controls the drug release time within the range of 3˜24 hours, and reduces the variability in the effect of drugs among individuals. Also, this composition can be produced into a sustained-release preparation which has an optimum condition for expressing the effect of drugs in the treatment of diseases including pulmonary arterial hypertension, hepatic portal vein hypertension, benign prostatic hyperplasia, and the like, which can be treated by udenafil and which requires the long-term drug administration.

Abstract: This invention relates to a single-liquid pharmaceutical composition for injection containing docetaxel. The composition includes (A) docetaxel and pharmaceutically acceptable salts thereof, (B) a surfactant selected from the group consisting of polysorbate, polyoxyethylene glycol ester and polyoxyethylene castor oil derivatives, (C) a solvent comprising anhydrous ethanol in a concentration range of 100 to 800 mg/ml, in an injectable solution, and (D) a pH adjuster of an amount suitable for adjusting the pH of the liquid composition to 5 or less. The composition may be directly diluted in a perfusion liquid even without the use of an intermediary dilute solution in case the composition is used for injectable preparations since the composition is in a single liquid phase. Furthermore, the composition is suitable for effective administration of docetaxel since the pharmaceutical stability of the composition is significantly improved.

Abstract: The present invention provides a 3?,4?,5-trimethoxy flavone derivative and a pharmaceutically acceptable salt thereof, preparation thereof, and a pharmaceutical composition for the treatment and prevention of dry eye syndrome comprising the same as an active ingredient. The 3?,4?,5-trimethoxy flavone derivative and its pharmaceutically acceptable salt inhibit corneal damage through excellent stimulatory action on mucus secretion in the conjunctiva and therefore may be effective as a prophylactic or therapeutic agent for dry eye syndrome.